Treatment of linear IgA bullous dermatosis of childhood with flucloxacillin

- Abdulmajeed Alajlan, MD, Marwan Al-Khawajah, MD, Omar Al-Sheikh, MD, Fahad Al-Saif, MD, Saleh Al-Rasheed, MD, Ibrahim Al-Hoqail, MD, Issam R. Hamadah, MD

Background

Linear IgA bullous dermatosis of childhood is a rare autoimmune bullous disease that mainly affects preschool-aged children. Dapsone is considered the first-line therapy with prompt response from most patients. However, it may be contraindicated in certain conditions such as glucose-6-phosphate dehydrogenase deficiency.

Objective

We sought to assess the efficacy of flucloxacillin in the treatment of linear IgA bullous dermatosis.

Methods

This is an observational study in which all confirmed cases of linear IgA bullous dermatosis (by both histological and immunofluorescence studies) will be treated with flucloxacillin. Flucloxacillin will be continued according to the response or otherwise will be discontinued after 8 weeks in the case of resistance.

Results

We describe 7 patients with linear IgA bullous dermatosis of childhood treated with flucloxacillin. In 4 cases, it induced complete remission within 3 to 4 months of starting therapy with no relapses. In the other 3 cases, it successfully controlled the disease but with prompt relapse on discontinuation of the treatment.

Limitations

This is a case series study with a small number of patients.

Conclusion

Flucloxacillin may be considered among the first alternative therapies for linear IgA bullous dermatosis of childhood. Further evaluation of the efficacy and safety of the long-term use is required.

Online link: http://www.eblue.org/article/S0190-9622%2805%2904706-7/abstract